<DOC>
	<DOCNO>NCT00419952</DOCNO>
	<brief_summary>The purpose study determine effectiveness safety SYMBICORT® pMDI ( medication approve Food Drug Administration , FDA ) African American population .</brief_summary>
	<brief_title>A Comparison SYMBICORT® pMDI With Budesonide HFA pMDI African American Subjects With Asthma .</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Male Female , African American ( selfreported ) , ≥12 year age Moderate severe asthma require treatment inhale corticosteroid Diagnosis asthma least 6 month Subjects require treatment systemic corticosteroid ( e.g. , oral , parenteral , ocular ) Any significant disease disorder may jeopardize subject 's safety</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Moderate Asthma</keyword>
	<keyword>Severe Asthma</keyword>
</DOC>